Hui Liu

Xuzhou Medical College — China

Medicine · Health Sciences

22h-index2.4kcitations79works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(57), Virus-based gene therapy research(11), Immune Cell Function and Interaction(11), Viral Infectious Diseases and Gene Expression in Insects(10), Integrated Circuits and Semiconductor Failure Analysis(10)

Publications78 total

Do all roads lead to Rome? The heterogeneity of relapsed/refractory diffuse large B-cell lymphoma patients who achieved therapies response and received autologous stem cell transplantation in the era of new targeted drugs
Cell Transplantation·2025Open Access
Synergistic antitumor effects and mechanisms of KPT-330 combined with venetoclax in Acute Myeloid Leukemia
Blood·2025
Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma
Blood·2025Open Access
DYRK1A controls CD47 endocytic degradation and leukemia immune surveillance
Blood·2025
Stability testing of HPCs and MNCs from apheresis products
Immunobiology·2025Open Access
Prognostic value of the co-stimulatory molecule OX40 expression in Extranodal Natural Killer/T-cell Lymphoma
Annals of Medicine·2025Open Access
STABILITY TESTING OF HPCS AND MNCS FROM APHERESIS PRODUCTS
Cytotherapy·2025
A novel prognostic index for extranodal natural killer/T-cell lymphoma in the era of pegaspargase/L-asparaginase
Future Oncology·2024· 1 citedOpen Access
SINGLE-CELL TRANSCRIPTOME ANALYSIS REVEALS DISTINCT CHARACTERISTICS OF ANTI-CD22 CAR T-CELL INFUSION PRODUCTS ASSOCIATED WITH EFFICACY AND TOXICITY
Cytotherapy·2024· 1 cited
CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study
EClinicalMedicine·2024· 16 citedOpen Access
Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma
Cell Discovery·2024· 25 citedOpen Access
OA-07 Phase I Study of BCMA CAR-T using instant manufacturing platform or traditional production process for relapsed/refractory multiple myeloma therapy
Clinical Lymphoma Myeloma & Leukemia·2023
Data from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
2023Open Access
Figure S1, Figure S2, Figure S3, Figure S4 from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
2023Open Access
Table S1, Table S2, Table S3, Table S4 from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
2023Open Access
Data from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
2023Open Access
Figure S1, Figure S2, Figure S3, Figure S4 from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
2023Open Access
Table S1, Table S2, Table S3, Table S4 from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
2023Open Access
Reference gene selection for clinical chimeric antigen receptor T-cell product vector copy number assays
Cytotherapy·2023· 12 citedOpen Access
Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study
Cytotherapy·2023· 16 cited
page 1 of 4Next →

Frequent Co-authors

David F. Stroncek(7), Wenbin Qian(6), Lipei Shao(6), Steven L. Highfill(6), Sandhya R. Panch(6), Ping Jin(6), Francesco M. Marincola(5), Zhitao Ying(5), Wenyu Li(5), Jianqiu Wu(5), Zisong Zhou(5), Rongye Shi(5), Yihua Cai(5), Ena Wang(4), Haiyan Yang(4), Ye Guo(4), Dehui Zou(4), Daobin Zhou(4), Mingzhi Zhang(4), Su Yang(4)